Kolong TissueGene Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:20
Jan 23
Jan 23
Korean biotech rotation supports platform names
Korean biotech has bottomed enough that investors should not sell into fear; Alteogen's royalty disappointment does not break the platform story, and rotation within biotech favors names such as Alteogen, ABL Bio, and Kolong TissueGene.
MED
About Kolong TissueGene Investor Commentary
Across the available history and selected sources, Buzzberg tracks Kolong TissueGene across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jang Woo-jin.